Phoenix Modeling Language (PML) School

Introduction & nonlinear clearance

Learn how to build custom PK and PK/PD models in Phoenix WinNonlin.

Metabolite kinetics

Simultaneously model plasma data of a drug and metabolite following 5-minute infusion; metabolite clearance follows Michaelis-Menten kinetics.

Two-compartment repeated oral dosing

Fit multiple dose kinetic and dynamic data sequentially.

Simultaneous fitting of plasma and urine data

Fit IV data first then IV and PO data separately and simultaneously.

Target-mediated drug disposition

Model circulating plasma target with a TMDD model.

Enterohepatic recirculation

Model enterohepatic recirculation (EHC) after intravenous administration.

Allometry-elementary/complex dedrick plot

Simultaneously fit an allometric model to data from mouse, rat and man.

Turnover III: nonlinear disposition

Characterize turnover of an endogenous compound.

Analysis and comparison of link, turnover and receptor binding models

Fit a link-, turnover- and receptor binding model to data.

Analysis of a tissue growth/kill model

Analyze a tumor cell kill model after acute dosing.

Modeling inhibition of enzyme activity by means of turnover

Construction of a mechanistic turnover model.

Effect compartment III: IV infusion

Model response-time data with a link-model.

Turnover model 4: IV infusions

Apply a turnover model to multiple IV dosing response data.

Turnover model 1: repeated dosing I

Apply a turnover model to repeated po dosing response data.

Dose-response-time analysis I-IV

Analyze dose-response-time data with an instantaneous effect model.

Minimal physiologically-based pharmacokinetic model for Monoclonal Antibodies (mabs)

Construct the model graphically and fit plasma data from mAbs.

Target-mediated Drug Disposition (TMDD) modeling using the quasi-equilibrium assumption

Write a textual model according to Gibiansky (2008), fit and simulate mAb profiles.

Adaptive simulations: extending PML to trial simulations

A pre-clinical example to simulate a desired outcome.

Introduction to NONMEM-NLME comparisons

PK 1-compartment IV bolus model FOCE.

NONMEM-2-NLME

PK 2-compartment multiple dose-IV bolus Plasma and Urine QRPEM/IMP.

NONMEM-2-NLME

PK 2-compartment oral with Disease State covariate on V and CL.

NONMEM-2-NLME

Nonlinear elimination and model validation I: Bootstrap.

NONMEM-2-NLME

Mixed absorption and model validation II: VPC.

NONMEM-2-NLME

Running NONMEM and Phoenix NLME in the cloud.

NONMEM-2-NLME

PD indirect response with IV bolus dosing.

NONMEM-2-NLME

PKPD 1-compartment IV infusion—Emax with baseline, shape and effect.

Population PK modeling and virtual BE trial simulation for formulation optimization

NONMEM-NLME comparisons

PD time-to-event analysis.

NONMEM-NLME comparisons

PD count analysis.